44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today…
Tag: HF
Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner…
First Cohort of Heart Failure Specialists to Earn Heart Failure Certification (HF-Cert™) Announced by Heart Failure Society of America
ROCKVILLE, Md., June 7, 2023 /PRNewswire/ — The Heart Failure Society of America (HFSA) today announced the first cohort of heart failure (HF) providers to earn the Heart Failure Certification (HF-Cert). The multi-disciplinary certification recognizes HF providers who have demonstrated advanced-level knowledge […]
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American College of Cardiology’s 72nd Annual Scientific […]
Biobeat Demonstrates Prediction Capabilities of Its Devices in Heart Failure Patients under Diuresis
Peer-reviewed study published in Journal of Clinical Medicine validates the use of Biobeat’s wrist monitor for advanced noninvasive hemodynamic monitoring in HF patients PETAH TIKVA, Israel, Jan. 17, 2023 /PRNewswire/ — Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare […]
egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation
Company to focus on improving the quality of care for all cardiovascular patients in the U.S. ALISO VIEJO, Calif.–(BUSINESS WIRE)–On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, […]
OM1 Heart Failure Registry Reaches More than 140,000 Patients Prospectively Followed with Deep Clinical Data
Available for collaborations, analytics, and licensing for faster, more cost-effective access to research-grade heart failure data BOSTON, Jan. 28, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of […]
V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure
CAESAREA, Israel, Aug. 15, 2019 /PRNewswire/ — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough Device Designation for its interatrial […]
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
SAN DIEGO, July 16, 2019 /PRNewswire/ — Ambrx Inc. today announced that Bristol-Myers Squibb Company (“BMS”) has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential treatment of heart failure (“HF”). Long-acting Relaxin is […]